| Amygdala activity correlates with attentional bias in PTSD M El Khoury-Malhame, E Reynaud, A Soriano, K Michael, ... Neuropsychologia 49 (7), 1969-1973, 2011 | 133 | 2011 |
| Assessment of abuse potential of benzodiazepines from a prescription database using ‘doctor shopping’as an indicator V Pradel, C Delga, F Rouby, J Micallef, M Lapeyre-Mestre CNS drugs 24, 611-620, 2010 | 103 | 2010 |
| Use of proton pump inhibitors in adults in France: a nationwide drug utilization study M Lassalle, T Le Tri, M Bardou, M Biour, J Kirchgesner, F Rouby, ... European journal of clinical pharmacology 76, 449-457, 2020 | 87 | 2020 |
| Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade≥ 2 immune-related adverse events in patients with cancer M Allouchery, T Lombard, M Martin, F Rouby, M Sassier, C Bertin, ... Journal for immunotherapy of cancer 8 (2), 2020 | 80 | 2020 |
| Bevacizumab-induced serious side-effects: a review of the French pharmacovigilance database S Taugourdeau-Raymond, F Rouby, A Default, MJ Jean-Pastor, ... European journal of clinical pharmacology 68, 1103-1107, 2012 | 78 | 2012 |
| Antiparkinsonian drug‐induced sleepiness: a double‐blind placebo‐controlled study of L‐dopa, bromocriptine and pramipexole in healthy subjects J Micallef, M Rey, A Eusebio, C Audebert, F Rouby, E Jouve, S Tardieu, ... British journal of clinical pharmacology 67 (3), 333-340, 2009 | 65 | 2009 |
| Immune check point inhibitors-induced hypophysitis: a retrospective analysis of the French pharmacovigilance database J Garon-Czmil, N Petitpain, F Rouby, M Sassier, S Babai, ... Scientific reports 9 (1), 19419, 2019 | 55 | 2019 |
| Evidence of clonazepam abuse liability: results of the tools developed by the French Centers for Evaluation and Information on Pharmacodependence (CEIP) network E Frauger, V Pauly, V Pradel, F Rouby, J Arditti, X Thirion, ... Fundamental & clinical pharmacology 25 (5), 633-641, 2011 | 53 | 2011 |
| Assessment of abuse of tianeptine from a reimbursement database using ‘doctor‐shopping’as an indicator F Rouby, V Pradel, E Frauger, V Pauly, F Natali, P Reggio, X Thirion, ... Fundamental & clinical pharmacology 26 (2), 286-294, 2012 | 48 | 2012 |
| Thrombotic microangiopathy associated with gemcitabine use: Presentation and outcome in a national French retrospective cohort F Daviet, F Rouby, P Poullin, J Moussi‐Francès, M Sallée, S Burtey, ... British journal of clinical pharmacology 85 (2), 403-412, 2019 | 44 | 2019 |
| Acute coronary syndrome with immune checkpoint inhibitors: a proof-of-concept case and pharmacovigilance analysis of a life-threatening adverse event J Cautela, F Rouby, JE Salem, J Alexandre, U Scemama, C Dolladille, ... Canadian Journal of Cardiology 36 (4), 476-481, 2020 | 38 | 2020 |
| Paradoxical pustular psoriasis induced by ustekinumab in a patient with Crohn’s disease-associated spondyloarthropathy M Benzaquen, B Flachaire, F Rouby, P Berbis, S Guis Rheumatology international 38 (7), 1297-1299, 2018 | 38 | 2018 |
| Artificial intelligence for unstructured healthcare data: application to coding of patient reporting of adverse drug reactions L Létinier, J Jouganous, M Benkebil, A Bel‐Létoile, C Goehrs, A Singier, ... Clinical Pharmacology & Therapeutics 110 (2), 392-400, 2021 | 36 | 2021 |
| Which indicators can public health authorities use to monitor prescription drug abuse and evaluate the impact of regulatory measures? Controlling High Dosage Buprenorphine abuse V Pauly, E Frauger, V Pradel, F Rouby, J Berbis, F Natali, P Reggio, ... Drug and alcohol dependence 113 (1), 29-36, 2011 | 35 | 2011 |
| Occurrence of type 1 and type 2 diabetes in patients treated with immunotherapy (anti-PD-1 and/or anti-CTLA-4) for metastatic melanoma: a retrospective study ML Gauci, P Boudou, B Baroudjian, T Vidal-Trecan, L Da Meda, ... Cancer Immunology, Immunotherapy 67, 1197-1208, 2018 | 33 | 2018 |
| Brain networks are independently modulated by donepezil, sleep, and sleep deprivation J Wirsich, M Rey, M Guye, C Bénar, L Lanteaume, B Ridley, ... Brain topography 31, 380-391, 2018 | 30 | 2018 |
| Estimation of clonazepam abuse liability: a new method using a reimbursed drug database E Frauger, V Pauly, X Thirion, F Natali, V Pradel, P Reggio, F Rouby, ... International clinical psychopharmacology 24 (6), 318-324, 2009 | 30 | 2009 |
| Use of intravenous immunoglobulins in clinical practice: data from three French university hospitals E Frauger, J Grassi, V Pradel, C Bornet, F Rouby, J Delorme, S Ousset, ... Fundamental & clinical pharmacology 25 (6), 753-761, 2011 | 28 | 2011 |
| Pyoderma gangrenosum arising during treatment of psoriasis with adalimumab: effectiveness of ustekinumab M Benzaquen, J Monnier, Y Beaussault, F Rouby, P Berbis Australasian Journal of Dermatology 58 (4), e270-e271, 2017 | 24 | 2017 |
| Proton pump inhibitors prescriptions in France: Main trends from 2006 to 2016 on French health insurance database Q Boucherie, F Rouby, D Frankel, P Roll, J Micallef Therapies 73 (5), 385-388, 2018 | 23 | 2018 |
